Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched Cohort Study

Alattar et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.08.011, Nov 2021 (preprint)
Early treatmentPSM retrospective · 774 patients · Qatar · May – Jul 2020
Favipiravir for COVID-19
Outcome
Improvement
Relative Risk · 95% CI
Improved viral clearance with favipiravir
p = 0.0000014
PSM retrospective with 1,493 patients, showing significantly improved viral clearance with favipiravir. There were no significant differences in clinical improvement or mortality. Mortality was lower (2.1% vs 3.1%), without statistical significance with the small number of events.
Potential risks of favipiravir include kidney injury1-3, liver injury2-5, cardiovascular events5,6, pulmonary toxicity6,7, and mutagenicity, carcinogenicity, teratogenicity, embryotoxicity, and the creation of dangerous variants8-14.
OutcomeImprovementEffect · pTreatmentControl
risk of death 33.3% lower · RR 0.67 · p = 0.50 33.3% lowerRR 0.67p = 0.50 8 of 387 (2.1%) 12 of 387 (3.1%) treatment 8 of 387 (2.1%), control 12 of 387 (3.1%)NNT 97propensity score matchingday 28
risk of no clinical improvement 2.2% higher · RR 1.02 · p = 0.73 2.2% higherRR 1.02p = 0.73 26 of 387 (6.7%) 28 of 387 (7.2%) treatment 26 of 387 (6.7%), control 28 of 387 (7.2%)day 28, Cox proportional hazardsNNT 194adjusted per studyinverted to make RR<1 favor treatmentpropensity score matchingprimary outcome
days to clinical improvement 6.2% higher · relative time 1.06 · p = 0.07 6.2% higherrelative time 1.06p = 0.07 387 387 treatment 387, control 387propensity score matching
risk of no viral clearance 43.9% lower · RR 0.56 · p < 0.001*** 43.9% lowerRR 0.56p < 0.001*** 78 of 387 (20.2%) 139 of 387 (35.9%) treatment 78 of 387 (20.2%), control 139 of 387 (35.9%)NNT 6.3propensity score matching

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. *** p < 0.001

Alattar et al., 30 Nov 2021, retrospective, Qatar, peer-reviewed, median age 46.0, 25 authors, study period 23 May, 2020 - 18 July, 2020, average treatment delay 5.0 days. Contact: aomrani@hamad.qa.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 Qatar Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Iceland New Zealand Mongolia Belarus Israel Haiti Hong Kong Panama Serbia Qatar favored high-profit treatments.The average efficacy of treatments was moderate.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 Qatar Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Mongolia Belarus Israel Hong Kong Panama Serbia Qatar favored high-profit treatments.The average efficacy was moderate.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
Rand A Alattar, Shiema Abdalla, Tasneem Abdallah, Rashid Kazman, Aseelah Qadmour, Tawheeda Ibrahim, Bassem Alhariri, Shahd H Shaar, Abeer Bajwa, Abeir Alimam, Rabia Qazi, Fatma Ben Abid, Joanne Daghfal, Ali Eldeeb, Kinda Shukri, Ahmed Elsayed, Fatima Rustom, Musaed Alsamawi, Alaaeldin Abdelmajid, Miguel A P Basulto, Armando A R Cobian, Mohamed Abukhattab, Abdullatif Alkhal, Muna A Almaslamani, Ali S Omrani
Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.08.011
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Ethical approval The study was approved by the Institutional Review Board at Hamad Medical Corporation (MRC-01-20-994), with a waiver of informed consent. Funding The publication of this article was funded by the Qatar National Library. J o u r n a l P r e -p r o o f Declaration of Interest None
References
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19 -Final Report, N Engl J Med, doi:10.1056/NEJMoa2007764
Cevik, Kuppalli, Kindrachuk, Peiris, Virology, transmission, and pathogenesis of SARS-CoV-2, BMJ, doi:10.1136/bmj.m3862
Doi, Hibino, Hase, Yamamoto, Kasamatsu et al., A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19, Antimicrob Agents Chemother, doi:10.1128/AAC.01897-20
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci, doi:10.2183/pjab.93.027
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin Infect Dis, doi:10.1093/cid/ciaa1176
J O U R N A L P R E, -p r o o f
Kumagai, Murakawa, Hasunuma, Aso, Yuji et al., Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults, Int J Clin Pharmacol Ther, doi:10.5414/cp202388
Lagocka, Dziedziejko, Kłos, Pawlik, Favipiravir in Therapy of Viral Infections, J Clin Med, doi:10.3390/jcm10020273
Manabe, Kambayashi, Akatsu, Kudo, Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis, doi:10.1186/s12879-021-06164-x
Özlüşen, Kozan, Akcan, Kalender, Yaprak et al., Effectiveness of favipiravir in COVID-19: a live systematic review, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-021-04307-1
DOI record: { "DOI": "10.1016/j.jiph.2022.08.011", "ISSN": [ "1876-0341" ], "URL": "http://dx.doi.org/10.1016/j.jiph.2022.08.011", "alternative-id": [ "S187603412200212X" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched Cohort Study" }, { "label": "Journal Title", "name": "journaltitle", "value": "Journal of Infection and Public Health" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.jiph.2022.08.011" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences." } ], "author": [ { "affiliation": [], "family": "Alattar", "given": "Rand A.", "sequence": "first" }, { "affiliation": [], "family": "Abdalla", "given": "Shiema", "sequence": "additional" }, { "affiliation": [], "family": "Abdallah", "given": "Tasneem", "sequence": "additional" }, { "affiliation": [], "family": "Kazman", "given": "Rashid", "sequence": "additional" }, { "affiliation": [], "family": "Qadmour", "given": "Aseelah", "sequence": "additional" }, { "affiliation": [], "family": "Ibrahim", "given": "Tawheeda", "sequence": "additional" }, { "affiliation": [], "family": "Alhariri", "given": "Bassem", "sequence": "additional" }, { "affiliation": [], "family": "Shaar", "given": "Shahd H.", "sequence": "additional" }, { "affiliation": [], "family": "Bajwa", "given": "Abeer", "sequence": "additional" }, { "affiliation": [], "family": "Alimam", "given": "Abeir", "sequence": "additional" }, { "affiliation": [], "family": "Qazi", "given": "Rabia", "sequence": "additional" }, { "affiliation": [], "family": "Ben Abid", "given": "Fatma", "sequence": "additional" }, { "affiliation": [], "family": "Daghfal", "given": "Joanne", "sequence": "additional" }, { "affiliation": [], "family": "Eldeeb", "given": "Ali", "sequence": "additional" }, { "affiliation": [], "family": "Shukri", "given": "Kinda", "sequence": "additional" }, { "affiliation": [], "family": "Elsayed", "given": "Ahmed", "sequence": "additional" }, { "affiliation": [], "family": "Rustom", "given": "Fatima", "sequence": "additional" }, { "affiliation": [], "family": "Alsamawi", "given": "Musaed", "sequence": "additional" }, { "affiliation": [], "family": "Abdelmajid", "given": "Alaaeldin", "sequence": "additional" }, { "affiliation": [], "family": "Basulto", "given": "Miguel A.P.", "sequence": "additional" }, { "affiliation": [], "family": "Cobian", "given": "Armando A.R.", "sequence": "additional" }, { "affiliation": [], "family": "Abukhattab", "given": "Mohamed", "sequence": "additional" }, { "affiliation": [], "family": "Alkhal", "given": "Abdullatif", "sequence": "additional" }, { "affiliation": [], "family": "Almaslamani", "given": "Muna A.", "sequence": "additional" }, { "affiliation": [], "family": "Omrani", "given": "Ali S.", "sequence": "additional" } ], "container-title": "Journal of Infection and Public Health", "container-title-short": "Journal of Infection and Public Health", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.fr", "clinicalkey.jp", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2022, 8, 27 ] ], "date-time": "2022-08-27T23:56:42Z", "timestamp": 1661644602000 }, "deposited": { "date-parts": [ [ 2022, 8, 27 ] ], "date-time": "2022-08-27T23:56:51Z", "timestamp": 1661644611000 }, "indexed": { "date-parts": [ [ 2022, 8, 28 ] ], "date-time": "2022-08-28T00:12:51Z", "timestamp": 1661645571683 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2022, 8 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 8, 1 ] ], "date-time": "2022-08-01T00:00:00Z", "timestamp": 1659312000000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 21, "start": { "date-parts": [ [ 2022, 8, 22 ] ], "date-time": "2022-08-22T00:00:00Z", "timestamp": 1661126400000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S187603412200212X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S187603412200212X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "prefix": "10.1016", "published": { "date-parts": [ [ 2022, 8 ] ] }, "published-print": { "date-parts": [ [ 2022, 8 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.2183/pjab.93.027", "article-title": "Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase", "author": "Furuta", "doi-asserted-by": "crossref", "first-page": "449", "journal-title": "Proc Jpn Acad Ser B Phys Biol Sci", "key": "10.1016/j.jiph.2022.08.011_bib1", "volume": "93", "year": "2017" }, { "DOI": "10.1007/s10096-021-04307-1", "article-title": "Effectiveness of favipiravir in COVID-19: a live systematic review", "author": "Özlüşen", "doi-asserted-by": "crossref", "first-page": "2575", "journal-title": "Eur J Clin Microbiol Infect Dis", "key": "10.1016/j.jiph.2022.08.011_bib2", "volume": "40", "year": "2021" }, { "DOI": "10.1056/NEJMoa2007764", "article-title": "Remdesivir for the Treatment of Covid-19 — Final Report", "author": "Beigel", "doi-asserted-by": "crossref", "first-page": "1813", "journal-title": "N Engl J Med", "key": "10.1016/j.jiph.2022.08.011_bib3", "volume": "383", "year": "2020" }, { "DOI": "10.1186/s12879-021-06164-x", "article-title": "Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis", "author": "Manabe", "doi-asserted-by": "crossref", "first-page": "489", "journal-title": "BMC Infect Dis", "key": "10.1016/j.jiph.2022.08.011_bib4", "volume": "21", "year": "2021" }, { "DOI": "10.1136/bmj.m3862", "article-title": "Virology, transmission, and pathogenesis of SARS-CoV-2", "author": "Cevik", "doi-asserted-by": "crossref", "first-page": "m3862", "journal-title": "BMJ", "key": "10.1016/j.jiph.2022.08.011_bib5", "volume": "371", "year": "2020" }, { "DOI": "10.3390/jcm10020273", "article-title": "Favipiravir in Therapy of Viral Infections", "author": "Lagocka", "doi-asserted-by": "crossref", "first-page": "273", "journal-title": "J Clin Med", "key": "10.1016/j.jiph.2022.08.011_bib6", "volume": "10", "year": "2021" }, { "article-title": "A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19", "author": "Doi", "first-page": "64", "journal-title": "Antimicrob Agents Chemother", "key": "10.1016/j.jiph.2022.08.011_bib7", "year": "2020" }, { "article-title": "Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19", "author": "RECOVERY", "first-page": "693", "journal-title": "N Engl J Med", "key": "10.1016/j.jiph.2022.08.011_bib8", "volume": "384", "year": "2020" }, { "DOI": "10.1016/S0140-6736(21)00676-0", "article-title": "Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial", "author": "RECOVERY Collaborative Group", "doi-asserted-by": "crossref", "first-page": "1637", "journal-title": "Lancet", "key": "10.1016/j.jiph.2022.08.011_bib9", "volume": "397", "year": "2021" }, { "DOI": "10.1093/cid/ciaa1176", "article-title": "AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial", "author": "Ivashchenko", "doi-asserted-by": "crossref", "first-page": "531", "journal-title": "Clin Infect Dis", "key": "10.1016/j.jiph.2022.08.011_bib10", "volume": "73", "year": "2020" }, { "DOI": "10.5414/CP202388", "article-title": "Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults", "author": "Kumagai", "doi-asserted-by": "crossref", "first-page": "866", "journal-title": "Int J Clin Pharmacol Ther", "key": "10.1016/j.jiph.2022.08.011_bib11", "volume": "53", "year": "2015" } ], "reference-count": 11, "references-count": 11, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S187603412200212X" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Public Health, Environmental and Occupational Health", "General Medicine" ], "subtitle": [], "title": "Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched Cohort Study", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy" }